{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-274405","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.209559+00:00","generated_at":"2026-05-16T22:17:33.053114+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"KalVista reports $13.7M Q3 net product revenue from EKTERLY launch; 937 patient start forms through Oct","bullets":["Net product revenue of $13.7M for Q3 ended Sept 30, 2025, first full quarter of EKTERLY commercial launch.","937 patient start forms received and 423 unique prescribers activated through Oct 31, 2025.","Cash and marketable securities of $309.2M; expects to fund through profitability.","EKTERLY approved in EU, Switzerland, and Australia; Germany launch initiated Oct 2025.","R&D expenses $12.0M (down from $18.7M); SG&A $46.5M (up from $24.8M) due to commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-274405","json":"https://secwatch.observer/filing/0001193125-25-274405.json","markdown":"https://secwatch.observer/filing/0001193125-25-274405.md","text":"https://secwatch.observer/filing/0001193125-25-274405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000119312525274405/0001193125-25-274405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000119312525274405/d43801d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:17:33.053114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}